Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL380204 | 1.00 | LDHA (0.33) | LDHASRR | |
| SCHEMBL891512 | 0.77 | HAO1 (0.44) | — | |
| SCHEMBL4731952 | 0.77 | HAO1 (0.44) | — | |
| Maleylacetoacetate SCHEMBL187565 | 0.75 | TSHR (0.45) | LDHASRR | |
| Maleylacetoacetate SCHEMBL187863 | 0.75 | TSHR (0.45) | LDHASRR | |
| Maleylacetoacetate SCHEMBL380205 | 0.75 | TSHR (0.45) | LDHASRR | |
| SCHEMBL6916408 | 0.73 | LDHA (0.36) | LDHASRR | |
| SCHEMBL6544742 | 0.71 | TRPA1 (0.41) | LDHASRR | |
| SCHEMBL2184678 | 0.69 | LDHA (0.67) | LDHASRR | |
| SCHEMBL28522 | 0.69 | LDHA (0.67) | LDHASRR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 280 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1487979-B2 | CONSTRUCTS AND METHODS FOR THE REGULATION OF GENE EXPRESSION | BASF PLANT SCIENCE GMBH (DE) | 2018-12-19 | — | — | EP | claimed |
| US-20170349949-A1 | METHODS OF SELECTING SUBJECTS FOR TREATMENT WITH METABOLIC MODULATORS | CLARIA PARTIKULA LLC | 2017-12-07 | — | — | US | claimed |
| EP-1487979-B1 | CONSTRUCTS AND METHODS FOR THE REGULATION OF GENE EXPRESSION | BASF PLANT SCIENCE GMBH (DE) | 2009-08-26 | — | — | EP | claimed |
| US-20050260754-A1 | Constructs and methods for the regulation of gene expression | KOCK, MICHAEL (DE) | 2005-11-24 | — | — | US | claimed |
| US-20040077020-A1 | A method that uses DNA microarray hybridization to identify patients with inflammatory bowel disease, and to distinguish Crohn's disease from ulcerative colitis | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2004-04-22 | — | — | US | claimed |
| US-20030066102-A1 | Plant gene for p-hydroxyphenylpyruvate dioxygenase | MAXWELL CARL ARTHUR (US) | 2003-04-03 | — | — | US | claimed |
| WO-2002059367-A2 | DIAGNOSTIC MICROARRAY FOR INFLAMMATORY BOWEL DISEASE, CROHN'S DISEASE AND ULCERATIVE COLITIS | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE (US) | 2002-08-01 | — | — | WO | claimed |
| EP-0914447-A1 | PLANT GENE FOR $i(P)-HYDROXYPHENYLPYRUVATE DIOXYGENASE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1999-05-12 | — | — | EP | claimed |
| WO-1997049816-A9 | PLANT GENE FOR P-HYDROXYPHENYLPYRUVATE DIOXYGENASE | — | 1998-03-26 | — | — | WO | claimed |
| WO-1997049816-A1 | PLANT GENE FOR P-HYDROXYPHENYLPYRUVATE DIOXYGENASE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-12-31 | — | — | WO | claimed |
| CN-122081190-A | Recombinant halomonas utilization of CO2And acetic acid as substrate for producing melanin | — | 2026-05-26 | — | — | CN | disclosed |
| US-12636381-B2 | In utero CRISPR-mediated therapeutic editing of genes | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2026-05-26 | — | — | US | disclosed |
| US-12428627-B2 | Mutant p-hydroxyphenylpyruvate dioxygenase, and coding nucleic acid and use thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUND CO., LTD. (CN) | 2025-09-30 | — | — | US | disclosed |
| EP-4593590-A1 | CORRECTION OF HEPATOSTEATOSIS IN HUMANIZED LIVER ANIMALS THROUGH RESTORATION OF IL6/IL6R/GP130 SIGNALING IN HUMAN HEPATOCYTES | Regeneron Pharmaceuticals, Inc. (US) | 2025-08-06 | — | — | EP | disclosed |
| EP-4557944-A1 | GENETICALLY MODIFIED ANIMAL MODEL AND ITS USE TO MODEL THE HUMAN IMMUNE SYSTEM | Regeneron Pharmaceuticals, Inc. (US) | 2025-05-28 | — | — | EP | disclosed |
| WO-1997049816-A9 | PLANT GENE FOR P-HYDROXYPHENYLPYRUVATE DIOXYGENASE | — | 1998-03-26 | — | — | WO | disclosed |
| WO-1997049816-A1 | PLANT GENE FOR P-HYDROXYPHENYLPYRUVATE DIOXYGENASE | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 1997-12-31 | — | — | WO | disclosed |
| US-5550165-A | CONTAINING 4-HYDROXYPHENYLPYRUVATE DIOXYGENASE INHIBITING AMOUNT OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE | ZENECA LIMITED (GB) | 1996-08-27 | — | — | US | disclosed |
| EP-0591275-A1 | USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE IN THE TREATMENT OF TYROSINAEMIA AND PHARMACEUTICAL COMPOSITIONS | ZENECA LIMITED (GB) | 1994-04-13 | — | — | EP | disclosed |
| WO-1993000080-A1 | USE OF 2-(2-NITRO-4-TRIFLUOROMETHYLBENZOYL)-1,3-CYCLOHEXANEDIONE IN THE TREATMENT OF TYROSINAEMIA AND PHARMACEUTICAL COMPOSITIONS | ZENECA LTD. (GB) | 1993-01-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12636381-B2 | In utero CRISPR-mediated therapeutic editing of genes | YARS1, TPH1, AARS1 | LDHA 594/4885SRR 1750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.